Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to Progression
Median time to progression of the cohort will be compared with equivalent measure in the literature.
18 months
No
David Loven, M.D.
Study Director
HaEmek Medical Center, Oncology Unit
Israel: Israeli Health Ministry Pharmaceutical Administration
0082-09-EMC
NCT01175772
August 2010
August 2013
Name | Location |
---|